Stochastic Modeling of HIV Reactivation Under ART Washout and Immune Fluctuations

Mesfin Asfaw Taye · 2025

Read Stochastic Modeling of HIV Reactivation Under ART Washout and Immune Fluctuations by Mesfin Asfaw Taye (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/arxiv-2503-19665.txt.

Introduction

Mesfin Taye presents a 2025 model of HIV rebound after treatment stops. Latent infected cells hide from the immune system, so stopping antiretroviral therapy usually lets the virus return. Standard models assume latent cells wake at a constant rate, but real reactivation is jittery, shaped by immune swings and drug decay. The author builds a Poisson-driven stochastic framework with drug washout that falls exponentially.

The model shows reactivation following structured waves, driven by immune cycles, daily rhythms, and passing inflammation, not a steady drip. Adding Gamma-distributed waiting times captures variation in wake-up timing across the reservoir. The author argues rebound risk is a moving target, not a fixed probability. The insight could sharpen cure strategies that time interventions to immune states.

Catalog record

CREATORMesfin Asfaw Taye
YEAR2025
COLLECTIONPAPERS
FORMATTXT
FILE SIZE70 KB
VERSION1.0
LICENSEhttp://creativecommons.org/licenses/by/4.0/
RIGHTSCC BY
SOURCEarXiv

Source: https://arxiv.org/abs/2503-19665

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Stochastic Modeling of HIV Reactivation Under ART Washout and Immune Fluctuations Mesfin Asfaw Taye Abstract Post-treatment HIV-1 rebound is dictated by the stochastic reactivation of latent reservoirs influenced by immune fluctuations and antiretroviral therapy (ART) decay. In this paper, we study the effects of time, immune variability, and ART pharmacokinetics on HIV reactivation following treatment interruption. In this work, we model latency reversal as a Poisson-driven stochastic process shaped by circadian rhythms, transient inflammation, and immune bursts. We incorporate gamma-distributed waiting times in order to capture heterogeneity in activation dynamics and confirm the reduced early post-ART reactivation. Building on earlier stochastic models of reactivation, we present a rigorous framework that captures a range of activation dynamics—including constant, sinusoidal, stochastic, and exponentially decaying rates—reflecting both immune-driven variability and pharmacokinetic influences on latency reversal. We further investigate block-and-lock strategies, showing that combining ART with latency-promoting agents pharmacologically stabilizes the reservoir and delays reactivation, particularly when drug decay is slow. In addition, we study a deterministic model describing the dynamics of viruses, latent cells, and infected cells, including the role of the immune response and the effect of shock-and-kill strategies. Our results reveal that synchronizing latency-reversing agents with immune activation cycles enhances viral clearance and delays rebound. This framework refines post-treatment control predictions and generalizes to persistent infections, such as hepatitis B virus (HBV) and cytomegalovirus (CMV), where immune fluctuations and drug decay shape stochastic viral reactivation. pacs Valid PACS appear here I Introduction The introduction of antiretroviral therapy (ART) has led to the improvement of HIV-1 management since the drug suppresses viral replication and delays disease progression [ 1 , 2 , 3 ] . However, a complete cure remains impossible due to long-lived, latently infected CD4 + T cells that are established early in infection [ 4 , 5 , 6 ] . These reservoirs persist via transcriptional silencing and immune evasion [ 7 , 8 , 9 ] . As a result, when treatment is interrupted, stochastic reactivation and rapid viral rebound occur [ 10 , 11 , 12 ] . Mathematical modeling has been pivotal for elucidating viral and latency dynamics [ 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 13 , 31 , 32 ] . However, most of these early deterministic approaches overlook the heterogeneity of reactivation, and it has recently been confirmed that latency dynamics are shaped by immune perturbations and environmental factors [ 33 , 34 , 35 , 36 ] . This warrants stochastic frameworks that incorporate reactivation variability, immune fluctuations, and ART pharmacokinetics to obtain improved rebound prediction [ 37 ] . Several stochastic models and mathematical frameworks have recently been developed to analyze complex biological and networked systems, including hepatitis B dynamics with media effects, co-infection modeling, Lévy-driven transmission, stochastic control strategies, delay-based vaccination models, and fractional-order epidemic systems [ 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 ] . Several empirical studies and non-human primate (NHP) trials indicate considerable heterogeneity in viral rebound timing following ART cessation [ 7 , 8 ] due to the interplay of immune thresholds, epigenetic regulation, and ART washout kinetics [ 9 ] . These research works confrim that early reactivation events are infrequent, with later rebounds shaped by circadian rhythms, inflammatory episodes, and immune activation bursts [ 34 , 35 ] . As these complexities are poorly captured by standard ordinary differential equation (ODE) models, stochastic differential equation (SDE) approaches that account for fluctuating reactivation rates and immune-mediated clearance [ 12 , 46 ] are required. Frequency-dependent models further include variability in latency reversal, immune surveillance, and ART pharmacodynamics [ 31 , 32 ] . Laboratory and in vivo studies have significantly advanced our understanding of HIV latency. Moreover Jurkat-derived T cell lines have shown mechanisms of chromatin-based silencing, while primary CD4 + T cell models better capture the heterogeneity of latent reservoirs [ 47 , 48 ] . In non-human primates (NHPs), latency-reversing agents (LRAs) and immune-based therapies have been evaluated [ 49 ] , with combination approaches, such as Toll-like receptor (TLR) agonists paired with broadly neutralizing antibodies (bNAbs) and this shows greater efficacy in delaying viral rebound than monotherapies [ 50 ] . Despite progress in targeting HIV latency, still several key challenges remain. Single-agent latency-reversing agents (LRAs) have shown limited efficacy, which highlights the need for combination approaches that pair reactivation with immune clearance [ 51 , 50 ] . The stochastic nature of reactivation suggests that interventions should align with periods of heightened immune responsiveness [ 7 , 10 ] . Moreover, reservoir heterogeneity, immune variability, and unpredictable latency dynamics continue to hinder sustained ART-free remission [ 34 , 36 , 52 ] and this calls for better strategies that integrate immunological targeting with individualized treatment dynamics. In this work, we develop both stochastic and deterministic models in order to study HIV reactivation dynamics following ART interruption. The stochastic framework includes time-dependent activation rates, gamma-distributed latency times, and pharmacokinetic drug decay in order to capture the effects of circadian rhythms, immune fluctuations, and heterogeneous reactivation. We analyze multiple activation profiles such as constant, sinusoidal, stochastic, and decaying rates. We then derive analytical expressions for cumulative activation, survival probability, and viral load. We further investigate block-and-lock strategies, showing that combining ART with latency-promoting agents pharmacologically stabilizes the reservoir and delays reactivation, particularly when drug decay is slow. Complementing this, our deterministic model captures the coupled dynamics of latent, infected, and target cells under time-varying ART and LRA exposures. Overall, these models show that immune-driven fluctuations lead to clustered reactivation events and slow ART washout delays rebound. Optimal post-treatment control can be achieved when latency-reversing agents are administered during immune activation peaks and ART clearance is gradual. This unified framework provides mechanistic insights and quantitative guidance for optimizing the timing and efficacy of shock-and-kill interventions. The remainder of this paper is structured as follows. In Section II, we discuss the Poisson process of HIV reactivation. In Section III, we consider HIV reactivation with a gamma-distributed waiting time. In Section IV, we present a mathematical model of viral reactivation. We study the dynamics of the virus, latent cells, and infected cells. In Section V, we present the shock and kill mathematical model. Section VI presents the summary and conclusions. II Poisson Process for HIV Reactivation with Drug Washout Based on the work Wu et al. [ 53 ] , we develop a rigorous time-dependent Poisson model to study HIV reactivation under four activation profiles: constant, sinusoidal, stochastic, and exponentially decreasing during ART washout. The exact solutions for cumulative activation and inter-event times reveal how rate variability drives event clustering and rebound dynamics. We extend this with an SDE framework integrating immune fluctuations and ART pharmacokinetics. This captures how drug decay and stochastic perturbations shape latency reversal. II.1 Stochastic Reactivation with Constant Activation Rate A fundamental challenge in understanding post-treatment HIV reactivation comes from the stochastic nature of latency reversal and viral rebound following antiretroviral therapy (ART) cessation. In this work, by developing a Poisson-driven stochastic framework that accounts for immune

Read the complete text